Nonsmoking medicine market in KRW 100 billion… Pfizer in profit
Kim Ji Seob | cloud50@ | 2018-03-14 11:13:38
According to the government`s` Support for Smoking Cessation Therapy `project, the market for anti-smoking medicines, which had been around KRW 10 billion in 2014, has risen by nearly 10 times to about KRW 100 billion this year, while Korea Pfizer Pharmaceutical`s` CHAMPIX (ingredient name: Varenicline).
According to the drug market research institute IQVIA on March 13, Pfizer Pharmaceutical`s anti-smoking drug Champex grew 33.16% YoY to KRW 65 billion last year. It grew nearly 10 times in a few years from 6.3 billion won in 2014. In 2015, Champex increased its usage in Korea due to government policies to support the purchase of cigarette remedies and smoking cessation supplements.
Meanwhile, sales of other products covered by the same policy were relatively low. South Korea`s Johnson & Johnson`s non-smoking gum `Nicolet` posted sales of KRW4.2 billion, up 10.89% from a year earlier. Samyang BioPharm`s NICOSTOP registered a 5.4% YoY decrease of KRW2.2 billion, `Is a year-on-year increase of 0.64% to KRW 1.6 billion.
GSK`s specialty drug Welbutrin (ingredient name bupropion), which treats nicotine dependence after smoking cessation, is expected to become more influential in the market, but its sales last year alone amounted to only W1.2bn as generic drugs were poured out. Hanmi Pharmaceutical`s "NIKOPION", a well-known botulinum transcription drug, was also expected to take place in the market with the prescription of KRW 4.2 billion in 2015, but dropped to KRW 1.3 billion in 2016 and KRW 0.8 billion last year. The same bupropion replacement drug, Myungin Pharm `HealthPION`, was also worth a mere 200 million won last year.
Therefore, a representative from Korea Pfizer Pharmaceutical Champex said, "Champex proved its efficacy and safety through the announcement of the global clinical trial `EAGLES`, which was one of the world`s largest smoking cessation treatments in January of last year. Based on this, And the recommendation of Champex`s monotherapy as a first-line drug. "The Korean Tuberculosis and Respiratory Society recommends that the barrenicin effect is 1.57 times higher than nicotine replacement and 1.69 times higher than bupropion.
Korean pharmaceutical companies are following up on their success. Barney Klein, the main ingredient of Champex, will be developed until July 19, 2020 to release a new drug that avoids the patent of a substance by changing the "salt", an additive component of the drug, It is progressing. According to the Food and Drug Administration, 28 applications were filed by Hanmi Pharm, Cheil Pharmaceutical, and Kolmar Korea until January. If domestic pharmaceutical companies succeed in avoiding the patent, they will be able to release products with the same ingredients as Champex in November, which should change the market for anti-smoking drugs.
By Kim Ji Seob cloud50@
[ copyright ⓒ The Digitaltimes ]
According to the drug market research institute IQVIA on March 13, Pfizer Pharmaceutical`s anti-smoking drug Champex grew 33.16% YoY to KRW 65 billion last year. It grew nearly 10 times in a few years from 6.3 billion won in 2014. In 2015, Champex increased its usage in Korea due to government policies to support the purchase of cigarette remedies and smoking cessation supplements.
Meanwhile, sales of other products covered by the same policy were relatively low. South Korea`s Johnson & Johnson`s non-smoking gum `Nicolet` posted sales of KRW4.2 billion, up 10.89% from a year earlier. Samyang BioPharm`s NICOSTOP registered a 5.4% YoY decrease of KRW2.2 billion, `Is a year-on-year increase of 0.64% to KRW 1.6 billion.
GSK`s specialty drug Welbutrin (ingredient name bupropion), which treats nicotine dependence after smoking cessation, is expected to become more influential in the market, but its sales last year alone amounted to only W1.2bn as generic drugs were poured out. Hanmi Pharmaceutical`s "NIKOPION", a well-known botulinum transcription drug, was also expected to take place in the market with the prescription of KRW 4.2 billion in 2015, but dropped to KRW 1.3 billion in 2016 and KRW 0.8 billion last year. The same bupropion replacement drug, Myungin Pharm `HealthPION`, was also worth a mere 200 million won last year.
Therefore, a representative from Korea Pfizer Pharmaceutical Champex said, "Champex proved its efficacy and safety through the announcement of the global clinical trial `EAGLES`, which was one of the world`s largest smoking cessation treatments in January of last year. Based on this, And the recommendation of Champex`s monotherapy as a first-line drug. "The Korean Tuberculosis and Respiratory Society recommends that the barrenicin effect is 1.57 times higher than nicotine replacement and 1.69 times higher than bupropion.
Korean pharmaceutical companies are following up on their success. Barney Klein, the main ingredient of Champex, will be developed until July 19, 2020 to release a new drug that avoids the patent of a substance by changing the "salt", an additive component of the drug, It is progressing. According to the Food and Drug Administration, 28 applications were filed by Hanmi Pharm, Cheil Pharmaceutical, and Kolmar Korea until January. If domestic pharmaceutical companies succeed in avoiding the patent, they will be able to release products with the same ingredients as Champex in November, which should change the market for anti-smoking drugs.
By Kim Ji Seob cloud50@